CFRX ContraFect Corporation

1.70
0  -3%
Previous Close 1.75
Open 1.85
Price To book 3.74
Market Cap 70.82M
Shares 41,656,000
Volume 23,714
Short Ratio 2.21
Av. Daily Volume 45,245

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced January 6, 2017 that its Phase 2 trial initiation has been delayed until mid-2017.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
  2. ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
  3. CFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017
  4. CORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  5. ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  6. ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
  7. Lisa Ricciardi to Join Board of Directors
  8. ContraFect Provides Program Update
  9. ContraFect to Present at Biotech Showcase 2017 Conference
  10. Is ContraFect Corp (CFRX) A Good Stock To Buy?
  11. ContraFect Corp. :CFRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  12. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  13. ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
  14. ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
  15. ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
  16. ContraFect to Present at The Lysin Meeting
  17. ContraFect Reports Third Quarter 2016 Financial Results and Provides Business Update
  18. CFRX: CF-301 Phase 2 Study in Bacteremia to Initiate in 4Q16